PTO/SB/08a (08-03)
Approved for use through 97/31/2006, ONB 0651-0201
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE
to a collection of information unfers it contains a valid OMS control number.

| INFOR | MATION DISCLOSURE |
|--------------|---------------------------------|
| | MENT BY APPLICANT |
| | submission under 37 CFR 1.99) |
| (1101 101 1 | sabiniosion ander or or it isoy |

| Application Number | | 10567218 |
|------------------------|--------|-------------------|
| Filing Date | | 2006-02-03 |
| First Named Inventor | Ardjar | n DOMMISSE, ET AL |
| Art Unit | | 2662 |
| Examiner Name | | |
| Attorney Docket Number | | NL030954 |

| | | | | U.S. | PATENTS | | Remove | |
|----------------------|------------|--------------------------|---|-----------------------|---|---------------------------------|--------------------------------|--|
| Examiner Initial* | Cite No | Patent Number | Patent Number Nind Issue Date Name of Patentee or Applicant R | | Releva | Columns, nt Passag Appear | Lines where ges or Relevant | |
| | 1 | | | | | | | |
| If you wis | h to a | dd additional U.S. Paten | t citatio | ı n information pl | ease click the Add button. | | Add | |
| | | | U.S.P | ATENT APPLI | CATION PUBLICATIONS | | Remove | |
| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publication Date | Name of Patentee or Applicant of cited Document | | Lines where ges or Relevant | |
| | 1 | 20030011679 | A1 | 2003-01-16 | JUNG ET AL | | | |
| | 2 | 20030081835 | A1 | 2003-05-01 LIN ET AL | | | | |
| | 3 | 20030086498 | A1 | 2003-05-08 | LEE ET AL | | | |
| | 4 | 20020126912 | A1 | 2002-09-12 ROUVELLOU | | | | |
| | 5 | 20030072377 | A1 | 2003-04-17 | RUOL ET AL | | | |

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

| Application Number | | 10567218 |
|--------------------------|--------|-----------------|
| iling Date | | 2006-02-03 |
| irst Named Inventor | Ardjar | DOMMISSE, ET AL |
| Art Unit | | 2662 |
| xaminer Name | | |
| Manager Davids & Manager | nr. | NI 030064 |

| | 6 | 20030026478 | A1 | 2003-02 | :-06 | JONES ET AL | | | | | | | | |
|-----------------------|--|--|------------|-----------|----------|----------------|-------|---------------------|--------|--|---|---|---------------------|--|
| If you wis | If you wish to add additional U.S. Published Application citation information please click the Add button. Add | | | | | | | | | | | | | |
| | FOREIGN PATENT DOCUMENTS Remove | | | | | | | | | | | | | |
| Examiner Initial* | Cite No | Foreign Document Number ³ | | Country K | | | | Publication Date | App | me of Patented blicant of cited cument | | Pages,Colu where Rele Passages of Figures Ap | vant or Relevant | |
| | 1 | 0998146 | ₽ | | A1 | 2000-05-03 | MA | TSUSHITA COF | 8P | | | | | |
| | 2 | 0120912 | wo | | A1 | 2001-03-22 | KPE | ENV | | | | | | |
| | 3 | 9956247 | wo | | A1 | 1999-11-04 | KPE | ENV | | | | | | |
| If you wis | h to a | dd additional Foreign P | atent Do | cument | citation | information pl | ease | click the Add | button | Add | | | | |
| | | | NO | I-PATE | NT LITE | RATURE DO | CUM | IENTS | | Remove | | | | |
| Examiner Initials* | xaminer Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. | | | | | | | T5 | | | | | | |
| | 1 | THOMAS STOCKHAMMER, ET AL; JVT H26L Video Transmission in 3G Wireless Environments | | | | | | | | | | | | |
| If you wis | h to a | dd additional non-pater | t literatu | ire docui | ment cit | ation informat | ion p | lease click the | Add b | utton Add | j | | | |
| | | | | EX | AMINE | R SIGNATUR | E | | | | | | | |
| Evaminer | Signs | ature | | | | | | Date Conside | red | | | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EFS Web 2.0

| | Application Number | | 10567218 | |
|---|-----------------------------|----|-------------------|--|
| | Filing Date | | 2006-02-03 | |
| INFORMATION DISCLOSURE | First Named Inventor Ardjar | | n DOMMISSE, ET AL | |
| STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) | Art Unit | | 2662 | |
| (Not for Submission under or or it issue | Examiner Name | | | |
| | Attorney Docket Numb | er | NL030954 | |

See find. Codes of USPTO Planto Tocuments at view, USPTO, DOV or MFEP 901.04. * Enter office that all essed the document, by the love-later code (WIPO) Standard ST3.3. ** Frequence painted consenset, the inclusion on the pase of the region of the Engerent must proceed the sensel number of the pasent of the major of the important participance of the sensel number of the pasent of the pasent of the pasent of the sensel of the pasent o

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

| Application Number | | 10567218 | | |
|----------------------|--------|------------------------|--|--|
| Filing Date | | 2006-02-03 | | |
| First Named Inventor | Ardjar | Ardjan DOMMISSE, ET AL | | |
| Art Unit | | 2662 | | |
| Examiner Name | | | | |
| Attorney Docket Numb | er | NL030954 | | |

CERTIFICATION STATEMENT

| Please see 37 | CFR 1.97 | and 1.9 | to make the | appropriate | selection(s): |
|---------------|----------|---------|-------------|-------------|---------------|
|---------------|----------|---------|-------------|-------------|---------------|

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.5(r)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

| Signature | /Edward W. Goodman/ | Date (YYYY-MM-DD) | 2007-01-31 |
|------------|---------------------|---------------------|------------|
| Name/Print | Edward W. Goodman | Registration Number | 28613 |

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfing. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.